Latest Options News

New Hope Corporation has updated its final dividend details for FY2025, confirming a fully franked payout of 15 cents per share and revising the dividend reinvestment plan price to $4.01.

Ramelius Resources has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.05 per share for FY2025, alongside details of its Dividend Reinvestment Plan pricing.

WhiteHawk Limited has completed a significant share placement to Lakeba Group, bringing the investor into its top 10 shareholders and signaling a strategic partnership aimed at accelerating growth in cybersecurity and AI.

Vanguard Investments Australia has announced the Distribution Reinvestment Plan (DRP) issue prices for its suite of ETFs for the quarter ending 30 September 2025, outlining key dates and eligibility for investors.

XTC Lithium Limited will be delisted from the ASX after over two years of suspension, choosing instead to focus on advancing its Carachi Pampa Lithium Brine Project through partnerships and operational progress.

Critical Resources Limited has successfully completed the first tranche of its capital raising, issuing over 190 million shares and accompanying options to bolster its exploration projects. The company now awaits shareholder approval for director share issuance as it prepares for the second tranche.

Arafura Rare Earths has completed the second tranche of its A$80 million capital raising, issuing over 51 million shares and raising approximately A$9.8 million. The company is also progressing a share purchase plan aimed at raising an additional A$5 million.

Octava Minerals reports impressive bioleaching recoveries of critical minerals from its Byro project, prompting plans to acquire full ownership and expand exploration activities.

Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.

QMines Limited has announced a fully underwritten $1.5 million Share Purchase Plan for existing shareholders, complementing a recent $7.5 million placement to fund exploration at its Mt Mackenzie gold and silver project.

Chimeric Therapeutics reports encouraging Phase 1B data from its ADVENT-AML trial, showing safety and multiple complete responses in high-risk AML patients treated with CORE-NK combined with standard therapies.

Taiton Resources has raised $2 million through a share placement to fund drilling at its Challenger West and Highway projects, with further shareholder approvals pending.